Health Bulletin 24/January/2022

Here are Top Health stories of the day

Delhi: Cases dip, govt to bring up easing restrictions with L-G

Pay annual DNB course fee directly to NBE: Natboard tells NEET PG candidates

Through a recent notice, the National Board of Examinations (NBE) has informed about the payment of First-year course fee at the time of joining Diploma/ DNB seat at NBEMS Accredited Hospital.

The counseling for admission to Diploma and DNB Courses of NBEMS for admission session 2021 is being conducted by the Medical Counseling Committee (MCC) of DGHS, Govt. of India along with the counseling for MD/MS/PG Diploma seats.

For more details, check out the full story on the link below:

Pay Annual DNB Course Fee Directly To NBE: Natboard Tells NEET PG candidates

Patient not given treatment, 5 day delay in COVID-19 report: Hospital told to pay Rs 5 lakh compensation

Bengal-based Jagannath Gupta Institute of Medical Sciences and Hospital in Budge Budge has been ordered to pay a compensation of Rs 5 Lakh to the patient's family for keeping the patient in the hospital without providing him treatment. The order was issued by West Bengal Clinical Establishment Regulatory Commission (WBCERC) on Friday.

The family members of the patient alleged that the patient was 'driven out and 'turned down' by the hospital when his COVID positive reports arrived after almost 5 days.

For more information, check out the full story on the link below:

Patient Not Given Treatment, 5 Day Delay In COVID-19 Report: Hospital Told To Pay Rs 5 Lakh Compensation

Apple, Mylan lose US SC bids to challenge patent review rule

The U.S. Supreme Court on Tuesday turned back challenges by Apple Inc and drugmaker Mylan Laboratories Ltd to a rule change that made it harder to contest patents before the U.S. Patent and Trademark Office.

The internal rule, adopted in 2020 under former PTO director Andrei Iancu, gives judges at the agency's Patent Trial and Appeal Board greater discretion to reject challenges to the validity of specific patents.

For more information, check out the full story on the link below:

Apple, Mylan lose US SC bids to challenge patent review rule